StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 10.1 %
EVOK stock opened at $0.47 on Thursday. Evoke Pharma has a 12 month low of $0.40 and a 12 month high of $1.77. The company has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.71. The stock has a market cap of $4.06 million, a PE ratio of -0.26 and a beta of 0.36.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The company had revenue of $1.74 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- What Are Trending Stocks? Trending Stocks Explained
- MarketBeat Week in Review – 6/10 – 6/14
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How to invest in marijuana stocks in 7 steps
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
